TLSI at a glance
TriSalus Life Sciences, Inc. (TLSI, SEC CIK 1826667) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), TriSalus Life Sciences, Inc. (TLSI) reported revenue of $45.2 million (up 53.4% from FY2024) and a net loss of $39.2 million. Diluted EPS was -$1.84.
- As of September 30, 2026, 18 institutional investment managers tracked by SignalX reported holding TriSalus Life Sciences, Inc. (TLSI) shares worth $30.6 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Szela Mary T on November 18, 2026 of 34,328 shares at $2.59 per share.
- In the last 90 days, TLSI insiders reported 4 open-market purchases ($294K) and 4 open-market sales ($5K) on Form 4, a net purchase of $289K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $45.2M
- +53.4% vs prior year
- Insiders · 90 days
- 4 buys · 4 sells
- Net +$289K
- 13F holders
- 18 funds
- $30.6M · +1 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes from the December 31, 2025 Form 10-K risk factors
- Continued clinical-development risk, potential delays or unfavorable trial outcomes
- Continued regulatory risk, failure to obtain or maintain required approvals
- Continued liquidity risk, need for additional financing to support operations
- Continued commercialization risk, limited market acceptance of TriSalus products
Management Discussion & Analysis
- Q3 revenue $12.878M, up 11.3% YoY from $11.566M, driven by higher TriNav unit sales
- Gross margin 86.2% vs 83.5% YoY, with gross profit $11.095M vs $9.660M
- Sole TriNav product line, revenue growth driven by increased units and lower per-unit costs
- Cash $41.1M vs $20.4M at December 31, 2025, with nine-month operating cash use $21.884M
- $42.6M net public-offering proceeds, ongoing operating losses and need for additional capital highlighted as headwinds
AI summary of the TLSI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026 announced
- Full operating and financial details contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q3 revenue $12.9M, up 11.3% YoY, signaling continued TriNav adoption despite slower-than-expected salesforce productivity
- Gross margin expanded to 86.2% from 83.5%, while operating loss narrowed to $7.7M from $9.0M
Item 8.01: Other Events
- FDA 510(k) clearance received for TriNav Advance, removing a key U.S. regulatory barrier
- Commercialization expected to commence, creating potential revenue opportunity for TriSalus
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results released for quarter ended June 30, 2026
- Full operating metrics and management commentary contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $11.4M, up 1.7% year over year, signaling modest commercial growth despite expanded sales investment
- Gross margin improved to 86.8% from 83.9%, supported by lower TriNav unit costs
AI summaries of TLSI 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TLSI
Don't miss the next TLSI filing
- Alerts as it files. A push when TLSI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TLSI, by share count.
- Ask anything. An AI agent that reads every TLSI filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Szela Mary T | Buy | Nov 18, 2026 | 34,328 | $2.59 |
| Gordon Gary B. | Buy | Nov 17, 2026 | 10,000 | $2.20 |
| Szela Mary T | Buy | Nov 17, 2026 | 30,864 | $2.31 |
| Marshak Richard | Sell | Nov 16, 2026 | 544 | $2.43 |
| Wahlstrom Mats | Buy | Nov 12, 2026 | 50,000 | $2.24 |
| Stevens Jennifer | Sell | Oct 5, 2026 | 316 | $4.39 |
| Marshak Richard | Sell | Oct 5, 2026 | 325 | $4.39 |
| Szela Mary T | F | Oct 5, 2026 | 2,693 | $4.38 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $29.4M | $45.2M |
| Gross Profit | - | $25.3M | $38.2M |
| Operating Income | - | -$36.2M | -$26.9M |
| Net Income | - | -$30.0M | -$39.2M |
| Gross Margin | - | 86.1% | 84.6% |
| Op. Margin | - | -122.9% | -59.7% |
| Net Margin | - | -102.1% | -86.9% |
| Balance Sheet | |||
| Total Assets | $25.7M | $24.0M | $35.3M |
| Equity | - | -$25.9M | -$33.9M |
| ROE | - | 116.0% | 115.8% |
| Per Share | |||
| EPS | - | $-1.31 | $-1.84 |
| Cash Flow | |||
| Operating CF | -$50.0M | -$40.8M | -$18.0M |
| CapEx | - | $345K | $918K |
Source: XBRL data in TriSalus Life Sciences, Inc. (TLSI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate TLSI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 18 | $30.6M |
| Q2 2026 | 17 | $31.0M |
| Q1 2026 | 17 | $17.5M |
| Q4 2025 | 16 | $30.5M |
| Q3 2025 | 14 | $13.0M |
| Q2 2025 | 12 | $11.1M |
| Q1 2025 | 12 | $5.3M |
| Q4 2024 | 6 | $3.1M |
- Invesco Ltd+295.4K (+524%)
- State Street Corp+57.9K (+9%)
- Goldman Sachs Group+33.0K (+40%)
- Bank of America Corp+17.0K (+8%)
- Morgan Stanley+16.2K (+4%)
- BlackRock−48.1K (-2%)
- Wells Fargo & Co−30.3K (-68%)
- Northern Trust−27.7K (-7%)
- Vanguard Portfolio Management LLC−20.5K (-6%)
- Citigroup−20.3K (-90%)
- Millennium Management+36.1K
- D.E. Shaw & Co+12.5K
- FMR LLC (Fidelity)−2.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 112 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TLSI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 8-K | Sep 22, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | May 15, 2026 | - | - | |
| SC 13G | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
TLSI SEC filings: frequently asked questions
Are TLSI insiders buying or selling?
In the last 90 days, TriSalus Life Sciences, Inc. (TLSI) officers, directors and 10% owners reported 4 open-market purchases worth $294,205 by 3 insiders and 4 open-market sales worth $5,435 by 3 insiders on Form 4, a net purchase of $288,770. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TLSI stock?
As of September 30, 2026, the largest TriSalus Life Sciences, Inc. (TLSI) holders among the 13F filers tracked by SignalX were BlackRock ($11.3 million), Vanguard Capital Management LLC ($7.4 million), State Street Corp ($2.9 million), Morgan Stanley ($1.8 million), Northern Trust ($1.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TLSI's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), TriSalus Life Sciences, Inc. (TLSI) reported revenue of $45.2 million (up 53.4% from FY2024) and a net loss of $39.2 million. Diluted EPS was -$1.84. The figures come from the XBRL data in the 10-K.
What did TLSI report in its latest 8-K?
TriSalus Life Sciences, Inc. (TLSI) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026 announced.
What are the latest TLSI SEC filings?
TriSalus Life Sciences, Inc. (TLSI) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 19, 2026.
What is TLSI's SEC CIK number?
TriSalus Life Sciences, Inc. (TLSI)'s SEC Central Index Key (CIK) is 1826667. EDGAR lists every TLSI filing under that number.
Ask anything about TLSI
The research agent reads TLSI's filings, financials, insider trades and 13F holders, then answers with sources.